“…32,38 Studies included patients on warfarin (n=9), 18-20, 23, 30, 36, 37, 39, 44 non-vitamin K antagonist oral anticoagulants (NOACs) (n=8) 17,27,[31][32][33][34][35]41 or both (n=1). 46 Nine studies referred broadly to anticoagulants, 22,24,25,28,29,38,40,43,45 and three evaluated antithrombotics. 21,26,42 Seven studies reported the quality of warfarin therapy, measured by time in therapeutic range (TTR), 18,20,30,36,37,39,44 seven reported on health outcomes (thromboembolism, bleeding, mortality), 19,27,29,33,35,39,44 15 reported on oral anticoagulant (OAC) prescribing, 21-26, 31, 34, 38, 40, 42, 43, 45, 46 28 one on patient knowledge 32 , one on patient cognition, 17 two on patient satisfaction 17,28 , and three on medication adherence.…”